Aesthetic Management Partners is expanding autologous skin boosters with Cellenis Exo-ME, a point-of-care system that concentrates components from a patient’s own blood for aesthetic skin and scalp protocols. The system processes a standard blood draw into an autologous preparation containing extracellular vesicles, including exosomes, and bioactive proteins. Building on the existing Cellenis PRP platform, Exo-ME gives healthcare professionals another way to incorporate a patient’s own biology into individualized aesthetic treatments and hair-focused protocols.
The system responds to growing interest in personalized approaches to skin quality while extending blood-based treatments beyond traditional PRP applications. For Aesthetic Management Partners, adding Exo-ME broadens the Cellenis portfolio and gives aesthetic practices another service to incorporate into treatment offerings. Its point-of-care format may also help providers differentiate their services as demand grows for personalized skin boosters and autologous aesthetic options.
Image Credit: Aesthetic Management Partners
Why This Trend Is Growing
- Autologous Aesthetics
- Patient-derived preparations are reshaping cosmetic care by enabling personalized skin and scalp treatments based on an individual’s own biological materials.
- Point-of-care Bioprocessing
- Compact in-clinic systems create new service models by turning standard blood draws into specialized therapeutic preparations during routine appointments.
- Exosome-based Skin Care
- Extracellular vesicle-focused formulations are expanding regenerative beauty concepts beyond traditional PRP into more targeted aesthetic and hair protocols.
Industries Being Reshaped
- Medical Aesthetics
- Personalized biologic boosters offer clinics differentiated premium treatments that align with growing demand for minimally invasive skin quality solutions.
- Hair Restoration
- Blood-derived extracellular vesicle protocols provide a complementary pathway for scalp-focused services within broader regenerative hair care offerings.
- Bioprocessing Technology
- Automated concentration platforms support the commercialization of patient-specific biologic products in decentralized healthcare and wellness settings.
